麻豆传媒

 

Impact Ethics

Pharmaceutical Policy

SELECT MEDIA ARTICLES

Church, E. (22 Dec 2015). . Globe & Mail.

Belluz, J. (30 Oct 2012). Maclean's.

Belluz, J. (23 Oct 2012). Macleans.

Dolgin, E. (19 Oct 2012). Nature Medicine/ Spoonful of Medicine.

Zilio, M. (6 Nov 2012) iPolitics.

Waldie, P. (13 Jul 2012). The Globe and Mail.

McIlroy, A. (8 Jun 2012). The Globe and Mail.

Hoag, H. (5 Dec 2011). University Affairs.

Anonymous. (5 Oct 2011). The Cochrane Collaboration.

Globe Editor. (7 Sept 2011). The Globe and Mail.

The Gazette. (29 Aug 2011). Postmedia News.

Weeks, C. (29 Aug 2011). The Globe and Mail.

SELECT BLOGS

Herder, M. (21 Dec 2015). . All Trials..

Herder, M. (21 Dec 2015). . Impact Ethics .

Herder, M. (23 Jun 2014). ImpactEthics.ca.

SELECT PUBLICATIONS

Herder, M., & Krahn, T.M. .Healthcare Policy, 11(4), 70-81.

Herder, M. (22 Dec 2015). .Canadian Medical Association Journal  [PDF 192 KB - Open Access]. Early release, published at www.cmaj.ca.

Herder, M. Gibson, E., Graham, J., Lexchin, J. & Mintzes, B. (13 May 2014). CMAJ, 186(8), E287-E292.

Schuchman, M. (6 Aug 2013).
Miriam Schuchman, CMAJ.

Herder, M. (2011). CMAJ.

H茅bert P. & Fergusson D.A. (13 Jul 2010). CMAJ Editorial.

 

SELECT POLICY CONTRIBUTIONS

In November 2012, Fran莽oise Baylis presented to the Senate Committee, this time highlighting the need to ensure that [PDF - 133 KB].

The committee tabled its second report in March 2013, [PDF - 4.4 MB].

Fran莽oise Baylis' contribution on the need for post-appproval strategies for population sub-groups is referenced in the (page 23).

Herder, M. (2 May 2016). .  

听

Recent News

Lack of transparency around pharmaceutical drugs continues to undermine patient safety and public health. The problem stems from the fact that lots of evidence about a drug鈥檚 safety and effectiveness is never published and remains inaccessible. While Canada seemed to be on a path to breaking norms of relevant secrecy with the passage of , in March 2016 Health Canada published its about how it intends to interpret sections 21.1(3)(c), cementing an approach that has access to information regarding the safety and effectiveness of pharmaceuticals. The following letters from legal scholars, clinicians and researchers, and representatives of civil society are in response to Health Canada鈥檚 call for public commentary on its Draft Guidance. The letters call upon Health Canada to remove limitations on access to relevant information so as to exclude clinical data (relevant to drug safety and effectiveness) from the category of confidential business information.

  • Herder, M. et al. (24 May 2016). ".
  • Spelsberg, A. et al. (24 May 2016).
  • Lexchin, J. et al. (22 May 2016). .

Overview

Since 2012 Matthew Herder has published several papers, appeared before Parliamentary Committees on several occasions, and written a number of blogs and op-eds relating to pharmaceutical policy. These听works focus on a range of topics, from improving the听transparency of evidence behind听pharmaceutical interventions as well as regulatory decision-making to orphan drug听policy and investigations of national pharmacare.听听

In December 2013, the Government of Canada introduced . It was designed to improve Health Canada's ablity to collect post-market safety information and take action when a serious risk is identified. In June 2014, Herder [PDF - 311 KB] calling for further amendments to make evidence and regulatory work transparent, and to make it absolutely clear that transparency trumps commercial claims. Vanessa's Law was subsequently amended to include a number of transparency related provisions, and then passed by Parliament in November 2014.

Herder has worked since the passage of Vanessa's Law to ensure that the legal changes are appropriately implemented by Health Canada. In December 2015, he published an article on and generated a , calling on clinicians, researchers and others, to file requests with Health Canada听for access to听unpublished听information about pharmaceutical drugs. This was supported by a number of NGOs, including AllTrials, Sense麻豆传媒ScienceUSA, Evidence4Democracy, and Canadian Doctors For Medicare.听

In addition to these transparency related projects, Herder has written several papers relating to orphan drugs 鈥� therapies aimed at treating rare diseases. As a result of , in May 2016 he was invited to appear before the House of Commons' Standing Committee on Health in connection with its study about national pharmacare.听

Page last updated Spring 2016.